Akeso Advances Fourth ADC Candidate into Clinical Trials with NMPA Clearance for AK158D1 — Akeso, Inc.

Event summary

Akeso's bispecific ADC AK158D1 targeting EGFR/TROP2 received Phase I clinical trial clearance from China's NMPA on September 17, 2026.
AK158D1 is Akeso's fourth ADC candidate to enter clinical development and its second bispecific ADC.
The trial will evaluate AK158D1 in patients with advanced malignant solid tumors.
Akeso's clinical-stage ADC portfolio now includes AK146D1, AK138D1, AK157D1, and AK158D1.

The big picture

Akeso's expansion of its ADC portfolio underscores its strategy of integrating next-generation immuno-oncology approaches with advanced ADC platforms. The company is positioning itself as a leader in developing differentiated therapies for solid tumors, leveraging its technological expertise in bispecific antibodies. This move aligns with broader industry trends toward combination therapies and multi-targeted treatments in oncology.

What we're watching

Clinical Progress: The pace at which AK158D1 advances through Phase I trials will determine its potential as a differentiated therapy for advanced solid tumors.
Strategic Integration: How Akeso combines its IO2.0 and ADC2.0 platforms will shape its competitive positioning in next-generation oncology treatments.
Market Differentiation: Whether AK158D1 can overcome the limitations of single-target ADCs, including narrow tumor coverage and off-target toxicity.